Fortress Biotechprfa 25 Stock Price To Earnings To Growth
| CNB0 Stock | EUR 5.80 0.05 0.85% |
Fundamental analysis of FORTRESS BIOTECHPRFA allows traders to better anticipate movements in FORTRESS BIOTECHPRFA's stock price by examining its financial health and performance throughout various phases of its business cycle.
FORTRESS |
FORTRESS BIOTECHPRFA 25 Company Price To Earnings To Growth Analysis
FORTRESS BIOTECHPRFA's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, FORTRESS BIOTECHPRFA 25 has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all Germany stocks is 100.0% higher than that of the company.
FORTRESS Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses FORTRESS BIOTECHPRFA's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of FORTRESS BIOTECHPRFA could also be used in its relative valuation, which is a method of valuing FORTRESS BIOTECHPRFA by comparing valuation metrics of similar companies.FORTRESS BIOTECHPRFA is currently under evaluation in price to earnings to growth category among its peers.
FORTRESS Fundamentals
| Return On Equity | -1.43 | |||
| Return On Asset | -0.35 | |||
| Profit Margin | (1.17) % | |||
| Operating Margin | (2.63) % | |||
| Shares Owned By Institutions | 1.80 % | |||
| Revenue | 77.61 M | |||
| Gross Profit | (85.66 M) | |||
| EBITDA | (197.84 M) | |||
| Net Income | (42.98 M) | |||
| Cash And Equivalents | 289.9 M | |||
| Cash Per Share | 2.98 X | |||
| Total Debt | 98.04 M | |||
| Debt To Equity | 0.40 % | |||
| Current Ratio | 5.91 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (83.48 M) | |||
| Earnings Per Share | (0.82) X | |||
| Number Of Employees | 173 | |||
| Beta | 1.9 | |||
| Annual Yield | 0.12 % |
About FORTRESS BIOTECHPRFA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FORTRESS BIOTECHPRFA 25's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FORTRESS BIOTECHPRFA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FORTRESS BIOTECHPRFA 25 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in FORTRESS Stock
FORTRESS BIOTECHPRFA financial ratios help investors to determine whether FORTRESS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in FORTRESS with respect to the benefits of owning FORTRESS BIOTECHPRFA security.